Key Takeaways
- • Abry Partners successfully closed a $780 million continuation fund to extend its investment in healthcare technology company Centauri Health Solutions, marking a significant capital commitment to the sector.
- • The continuation vehicle was structured with Kirkland & Ellis LLP serving as legal counsel, underscoring institutional-grade deal execution and governance standards typical of large PE transactions.
- • The deployment of continuation capital signals Abry's confidence in Centauri Health Solutions' growth trajectory and the broader healthcare technology market opportunity, enabling extended value creation beyond the initial fund lifecycle.
- • Continuation funds allow PE firms to avoid forced exits and extend holding periods when portfolio companies demonstrate strong operational performance and market conditions remain favorable.
Summary
Abry Partners announced on June 15, 2026, the successful close of a $780 million continuation fund dedicated to its ongoing partnership with healthcare technology company Centauri Health Solutions. The vehicle represents a significant capital commitment by the Boston-based private equity firm to extend its stake in the healthcare tech sector, a space that has attracted substantial institutional capital amid ongoing digital transformation in healthcare delivery and operations.
Kirkland & Ellis LLP served as legal counsel on the transaction, reflecting the institutional-grade structuring and governance frameworks applied to the continuation fund arrangement. The use of established law firms for continuation vehicle documentation is standard practice among major PE firms, ensuring compliance with fiduciary requirements and investor agreements while protecting the fund's capital deployment strategy.
Continuation funds are employed by private equity investors when portfolio companies demonstrate sustained operational strength and market conditions support extended value creation timelines. Rather than executing a sale or IPO on a predetermined schedule, continuation vehicles allow PE sponsors to maintain control and further develop portfolio companies, potentially generating incremental returns through organic growth, bolt-on acquisitions, or operational improvements. The $780 million raise suggests robust investor appetite for Abry's healthcare technology thesis and confidence in Centauri's market position and management team.
The transaction reflects the broader institutional investment trend favoring healthcare technology solutions, driven by factors including population aging, regulatory pressure to reduce healthcare costs, and accelerating adoption of digital health and operational technology platforms. Abry's ability to deploy continuation capital at scale indicates strong investor conviction in both the firm's investment strategy and Centauri Health Solutions' competitive positioning within the healthcare tech ecosystem.
Kirkland & Ellis LLP served as legal counsel on the transaction, reflecting the institutional-grade structuring and governance frameworks applied to the continuation fund arrangement. The use of established law firms for continuation vehicle documentation is standard practice among major PE firms, ensuring compliance with fiduciary requirements and investor agreements while protecting the fund's capital deployment strategy.
Continuation funds are employed by private equity investors when portfolio companies demonstrate sustained operational strength and market conditions support extended value creation timelines. Rather than executing a sale or IPO on a predetermined schedule, continuation vehicles allow PE sponsors to maintain control and further develop portfolio companies, potentially generating incremental returns through organic growth, bolt-on acquisitions, or operational improvements. The $780 million raise suggests robust investor appetite for Abry's healthcare technology thesis and confidence in Centauri's market position and management team.
The transaction reflects the broader institutional investment trend favoring healthcare technology solutions, driven by factors including population aging, regulatory pressure to reduce healthcare costs, and accelerating adoption of digital health and operational technology platforms. Abry's ability to deploy continuation capital at scale indicates strong investor conviction in both the firm's investment strategy and Centauri Health Solutions' competitive positioning within the healthcare tech ecosystem.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.